###### Strengths and limitations of this study

-   A population-based study.

-   2151 included women.

-   High quality of data sources and complete information in the follow-up period for all included women.

-   Adjustment for several factors: age, procedure type, preoperative oestrogen use, comorbidity, educational level and personal annual income.

-   Redeemed prescriptions were used as a proxy for drug use.

-   No data on symptomatology, catheter usage, preoperative antibiotics or urine culture.

Introduction {#s1}
============

Urinary tract infection (UTI) is a common problem in women, and 40% of women have UTI during their life-time---of these, 27% have recurrent UTI within 12 months.[@R1] There are several risk factors for UTI and recurrent UTI; for example, high age, urogenital atrophy and urinary incontinence (UI).[@R2] [@R3] UI is associated with UTI,[@R2] [@R4] and UTI might be regarded as a comorbid condition in women with UI due to several factors including poor perineal hygiene.[@R5] Thus, it is not surprising that UTI is seen in women with UI, but no studies have so far examined the burden of UTI in women undergoing surgery for UI in a population-based setting.

It is also well known that UTI is common after UI surgery. Risk factors of postoperative UTI include previous recurrent UTI, postoperative catheterisation, positive urine cultures at day of surgery and preoperative postvoid residual.[@R6] UTI after UI surgery might occur among 6--38% of the women---depending on diagnostic methods and criteria.[@R8] [@R10] and surgery-related infections occur within 2 months.[@R17] Thus, while some knowledge of UTI exists in the short-term perspective after UI surgery, there is only little evidence on the frequency of UTI in a more long-term perspective after UI surgery.[@R8]

The purpose of this study was to examine the use of antibiotics for UTI before and after surgery for UI, and among women using antibiotics for UTI before surgery to estimate the risk of postoperative use in a short-term and long-term perspective. This topic is clinically highly relevant in the counselling of women prior to surgery for UI: What can they expect of postoperative complications? Can preoperative drug users expect to continue drug use after surgery?

Materials and methods {#s2}
=====================

Study population and settings {#s2a}
-----------------------------

Women were included in the study if they had a primary surgical procedure for UI within the period of 1 January 1996 through 31 December 2010. Data on performed procedures were retrieved from the Danish National Patient Registry (NPR)[@R18] according to codes listed in online supplementary appendix 1. The surgical procedures were performed in one of four hospitals in the county of Funen, Denmark, between 1 January 1996 and 31 December 2006 or for the period 2007 through 2010 in 1 of 13 hospitals in the new Region of Southern Denmark (including Funen). The extension of the area was due to a change in the organisation of the healthcare system in 2007, including a structural change from 14 counties to 5 regions. Women with concomitant or prior surgery for pelvic organ prolapse were included. Women younger than 18 years were excluded.

Data sources {#s2b}
------------

Data for this study were retrieved from three Danish registers: the NPR, Odense University Pharmacoepidemiologic Database (OPED), the Statistics Denmark. All Danish citizens are assigned a unique Civil Registration Number (CRN), which enables individual-level linkage across registries.[@R19]

The NPR contains data on discharges from public hospitals in Denmark, and the completeness of recordings has been estimated to be 99.4%.[@R20] Information available in the registry pertain to the CRN, the dates of admission, dates of discharge and discharge diagnoses, classified according to the International Classification of Diseases-8 (ICD-8) (1977--1993) and ICD-10 (1994 and onward)[@R21] [@R22] as well as codes from the Danish classification system of surgical procedures.[@R23]

Information on relevant drugs (antibiotics and oestrogens) was retrieved from the OPED for the period 1995 to 2011 for the entire study population.

The OPED is pharmacy-based and captures all reimbursed prescriptions, and contains person-identifiable data with complete coverage on all computerised prescription reimbursements from the county of Funen (population 2006: 479 000) from 1990 and from January 2007 onwards extended to the whole Region of Southern Denmark (population 1.2 million). The age and gender distribution of this population are very similar to that of the Danish population as a whole (2006: 5.4 million), and the prescribing of drugs is very similar to the national average.[@R24]

Prescription reimbursements are given independent of patient income to all legal inhabitants of Denmark as a part of the National Health Service. Each record includes the CRN, date of purchase, a full account of what have been dispensed, including the brand name and the Anatomical Therapeutic Chemical (ATC) classification code. Information not included in the prescription database is drugs sold over the counter or drugs not reimbursed by the county authority (mainly oral contraceptives, sedatives and hypnotics). Data on highest attained educational level and annual income were retrieved from the Danish Integrated Database for Labour Market Research at Statistics Denmark, a database with annually updated socioeconomic data for each Danish citizen, mainly supplied by tax authorities, educational institutions and employment services.[@R25]

Antibiotics under study {#s2c}
-----------------------

Included drugs were antibiotics traditionally used in Denmark exclusively or predominantly for the treatment of UTI (sulphamethizole (ATC J01EB02), pivmecillinam (ATC J01CA08), nitrofurantoin (ATC J01XE01), trimethoprim (ATC J01EA01), as well as mecillinam (ATC J01CA11))[@R26] [@R27] and with a duration of 3--5 days. The indications for the prescribed drugs are not registered in the OPED; therefore, pivampicillin and amoxicillin were not included---as these antibiotics are also commonly used in treatment of upper respiratory tract infections. Likewise, broader spectrum antibiotics such as cephalosporins and quinolones were not included, as they are not commonly used for UTIs in Denmark.

Exposed and unexposed cohorts {#s2d}
-----------------------------

Exposed cohort: All women ≥18 years undergoing a primary surgical procedure for UI between 1 January 1996 and 31 December 2010 in the county of Funen/Region of Southern Denmark, and having redeemed one or more prescriptions on antibiotics within 365 days preceding the date of surgery (index date).

Unexposed cohort: All women ≥18 years undergoing a primary surgical procedure for UI between 1 January 1996 and 31 December 2010 in the county of Funen/Region of Southern Denmark without having redeemed similar prescriptions within the same time frame.

Outcome data {#s2e}
------------

For both exposed and unexposed women, the outcome was use of antibiotics for UTI, defined as having redeemed at least one prescription for these antibiotics within (1) 60 days after the index date (short-term postoperative users) and (2) 61--365 days after the index date (long-term postoperative users). These outcomes were not mutually exclusive, that is, a woman might be classified as a short-term and long-term user, postoperatively.

Covariates {#s2f}
----------

The use of antibiotics might be affected by age, type of surgery, use of oestrogen, comorbidity, calendar time and the individuals' ability to pay for the medicine might be affected by educational level and annual income. Therefore, these variables were included in the analysis as potential confounders.

### Type of procedures {#s2f1}

The types of UI surgery were divided into four groups according to the surgical procedure code: (1) mid-urethral sling procedures with transobturator route (toMUS), (2) mid-urethral sling procedures with retropubic route (rpMUS), (3) bulking procedures and (4) other types of UI surgeries.

### Oestrogen {#s2f2}

Use of oestrogens (ATC G03C) was included in the analyses as a confounder.

To adjust for preoperative oestrogen use, preoperative users of oestrogens were defined as women who had redeemed at least one prescription for oestrogens within 365 days preceding the date of surgery and nonusers were defined as those who had no preoperative oestrogen use during the same period. The local and systemic oestrogens were included.

### Comorbidity {#s2f3}

The comorbidity was classified according to the validated, well-known and widely used Charlson comorbidity index (CCI),[@R28] which assigns different weights (1, 2, 3 and 6) to 20 different disease categories specified by medical condition and severity (eg, diabetes, cardiovascular diseases, chronic pulmonary, renal, liver and connective tissue diseases). The CCI was computed based on each woman\'s complete hospital discharge history from the NPR since 1977. A categorised version of the CCI score values was used: 0 (low), 1--2 (medium) and 3+ (high).[@R32]

### Education and income {#s2f4}

Information on educational level and annual income for each woman was retrieved as a measure of socioeconomic status. Educational level was categorised according to the highest attained educational level in the year of surgery: 'Basic' (basic school/high school education: 7--12 years of primary, secondary and grammar school education), 'Secondary' (vocational education, 10--12 years of education) and 'Higher' (a university degree or an examination in another higher institution requiring an average total of 13 years or more).[@R28]

On the basis of quartiles of annual income for each woman in the year of her surgery, we categorised women in low (1st quartile), medium (2nd and 3rd quartile) and high income (4th quartile).

Statistical analysis {#s2g}
--------------------

The use of antibiotics for UTI within the first 365 days after surgery for exposed and unexposed cohorts was illustrated in a flow chart. We also constructed contingency tables for the main study variables, and computed ORs, with 95% CIs.

To analyse the significance of preoperative antibiotic use as risk factor of postoperative use (within 60 days and within 61--365 days after surgery), adjusted ORs were estimated by means of multivariate logistic regression models.

Adjustment was made for age (18--39, 40--59 and ≥60 years (reference)), type of procedures (toMUS (reference), rpMUS, bulking, others), education (basic (reference), secondary, higher), annual income (low (reference), middle, high), comorbidity (CCI 0 (reference), CCI 1--2, CCI 3+), calendar year (1996--2006, 2007--2008 (reference), 2009--2010) and use of oestrogen within 365 days preceding the date of surgery (no (reference), yes).

Stratified analyses were performed according to the use of oestrogens before surgery to examine the association between the use of antibiotics for UTI in oestrogen users versus oestrogen non-users.

All analyses were performed using Stata Release V.12.0.

Results {#s3}
=======

A total of 2151 women had a primary surgical procedure for UI between 1 January 1996 and 31 December 2010; 2073 had a solitary UI surgery, and 78 had concomitant surgery for pelvic organ prolapse.

Of the 2151 women, 1655 (76.9%) women did not use antibiotics for UTI within 365 days preceding the date of surgery, while 496 (23.1%) did, and the majority (376/496=75.8%) redeemed ≤2 prescriptions preoperatively and only a minority (42/496=8%) redeemed more than five or more prescriptions. The use of antibiotics for UTI within 365 days after surgery is detailed for the exposed and unexposed cohorts in [figure 1](#BMJOPEN2013004051F1){ref-type="fig"}. The most commonly used antibiotics both preoperatively and postoperatively were sulphamethizol and pivmecillinam.

![Women (N=2151) with primary surgery for urinary incontinence (UI) and their use of antibiotics for urinary tract infection before and after surgery for UI. Exposed women had redeemed one or more prescriptions of antibiotics within 365 days preceding the date of surgery. Unexposed women had not redeemed prescriptions of antibiotics within 365 days preceding the date of surgery.](bmjopen2013004051f01){#BMJOPEN2013004051F1}

Women having redeemed prescriptions for antibiotics for UTI before surgery (exposed) {#s3a}
------------------------------------------------------------------------------------

Of the 496 women with prior use of antibiotics for UTI, 129 (26%) redeemed a prescription for antibiotics for UTI within 0--60 days after surgery, and of these, 85 (65.9%) also within 61--365 days after surgery ([figure 1](#BMJOPEN2013004051F1){ref-type="fig"}). A total of 215 (43.3%) continued to redeem prescriptions for antibiotics within 61--365 days ([figure 1](#BMJOPEN2013004051F1){ref-type="fig"}).

Women with no usage of antibiotics for UTI before surgery (unexposed) {#s3b}
---------------------------------------------------------------------

Of the 1655 women who did not redeem prescription before surgery, 182 (11%) women had a short-term use of antibiotics for UTI after surgery; and of these, 64 women were also long-term users ([figure 1](#BMJOPEN2013004051F1){ref-type="fig"}). Among unexposed without short-term postoperative use of antibiotics, 171 (10.3%) became long-term postoperative users ([figure 1](#BMJOPEN2013004051F1){ref-type="fig"}). The total number of women with long-term antibiotic use was 235 (14.2%).

Comparison of exposed and unexposed cohorts {#s3c}
-------------------------------------------

Baseline characteristics of exposed and unexposed women are presented in [table 1](#BMJOPEN2013004051TB1){ref-type="table"}. The most commonly used procedure was to MUS accounting for approximately half of the procedures performed in both the exposed and the unexposed group. The most commonly prescribed drugs prior to surgery were sulphamethizol and pivmecillinam. Compared with unexposed women, exposed women tended to be older, to be more frequent oestrogen users and to have higher comorbidity indices. There was no difference in educational level or personal annual income.

###### 

Baseline characteristics of all included women (N=2151) having a primary surgical procedure for UI in Denmark, 1996--2010

  -----------------------------------------------------------------------------------
                                                        Exposed\*\     Unexposed†\
                                                        n=496          n=1655
  ----------------------------------------------------- -------------- --------------
  Mean age (±SD), years (at time of first UI surgery)   60.2 (±13.2)   54.2 (±12.4)

  Age groups, n (%)                                                    

   18--39                                               30 (6.1)       182 (11.0)

   40--59                                               196 (39.5)     911 (55.1)

   60−                                                  270 (54.4)     562 (33.9)

  Procedures, n (%)                                                    

   rpMUS                                                140 (28.2)     535 (32.3)

   toMUS                                                222 (44.8)     750 (45.3)

   Bulking                                              110 (22.2)     250 (15.1)

   Others                                               24 (4.8)       120 (7.3)

  Concomitant prolapse surgery, n (%)                   12 (2.4)       66 (4.0)

  Antibiotics before surgery, n (%)‡                                   

   Sulfamethizol---J01EB02                              299 (60.3)     --

   Pivmecillinam---J01CA08                              288 (58.1)     --

   Nitrofurantoin---J01XE01                             65 (13.1)      --

   Trimethoprim---J01EA01                               45 (9.1)       --

   Mecillinam---J01CA11                                 0 (0)          --

  Oestrogen users, n (%)§                                              

   No                                                   211 (42.5)     997 (60.2)

   Yes                                                  285 (57.5)     658 (39.8)

  Comorbidity (CCI), n (%)                                             

   0                                                    298 (60.1)     1214 (73.4)

   1--2                                                 139 (28.0)     381 (23.0)

   3+                                                   59 (11.9)      60 (3.6)

  Educational level, n (%)¶                                            

   Basic                                                229 (47.4)     688 (42.3)

   Secondary                                            170 (35.2)     600 (36.8)

   Higher                                               84 (17.4)      340 (20.9)

  Annual income, n (%)                                                 

   Low (1st quartile)                                   152 (30.7)     385 (23.3)

   Middle (2nd--3rd quartile)                           252 (50.8)     825 (49.9)

   High (4th quartile)                                  92 (18.5)      445 (26.9)

  Year of surgery n (%)                                                

   1996--2006                                           106 (21.4)     353 (21.3)

   2007--2008                                           186 (37.5)     605 (36.6)

   2009--2010                                           204 (41.1)     697 (42.1)
  -----------------------------------------------------------------------------------

\*Exposed women had redeemed one or more prescriptions of antibiotics within 365 days preceding the date of surgery. †Unexposed women had not redeemed prescriptions of antibiotics within 365 days preceding the date of surgery.

‡Does not sum up to 100%. Some women redeemed more than one type of the drugs during the time period.

§Women with at least one redeemed prescription of oestrogen within 365 days preceding the date of surgery.

¶Unknown highest attained educational level: 40 women.

CCI, Charlson comorbidity index; rpMUS, retropubic mid-urethral sling, toMUS, trans-obturator mid-urethral sling.

The unadjusted OR of a prior antibiotic user being a postoperative short-term and long-term user was 2.8 (95% CI 2.2 to 3.7) and 4.6 (95% CI 3.7 to 5.8), respectively. The adjusted OR of being short-term and long-term user of antibiotics for UTI after surgery was 2.6 (95% CI 2.0 to 3.5) and 4.5 (95% CI 3.5 to 5.7), respectively ([table 2](#BMJOPEN2013004051TB2){ref-type="table"}). Thus, adjustment for confounders did virtually not change the relative risk estimates. The details from logistic regression models are presented in [table 2](#BMJOPEN2013004051TB2){ref-type="table"} showing the impact of each prognostic factor included. Regarding short-term use, the strongest risk factors were procedure types (rpMUS/others), high comorbidity index and preoperative antibiotic use. Preoperative use of antibiotics for UTI was the strongest risk factor of long-term postoperative use.

###### 

Risk factors of postoperative use of antibiotics

                                    Postoperative non-use   Postoperative short-term use   Postoperative non-use   Postoperative long-term use         
  --------------------------------- ----------------------- ------------------------------ ----------------------- ----------------------------- ----- ------------------
  Preoperative use                                                                                                                                     
   No                               1473                    182                            Reference               1420                          235   Reference
   Yes                              367                     129                            2.6 (2.0 to 3.5)        281                           215   4.5 (3.5 to 5.7)
  Age group                                                                                                                                            
   18--39                           185                     27                             0.9 (0.5 to 1.5)        163                           49    1.5 (0.9 to 2.3)
   40--59                           981                     126                            0.6 (0.5 to 0.9)        931                           176   0.7 (0.5 to 0.9)
   60−                              674                     158                            Reference               607                           225   Reference
  Procedure                                                                                                                                            
   rpMUS                            568                     107                            1.7 (1.1 to 2.7)        529                           146   1.3 (0.9 to 1.9)
   toMUS                            849                     123                            Reference               782                           190   Reference
   Bulking                          315                     45                             1.4 (0.9 to 2.0)        278                           82    1.1 (0.8 to 1.5)
  Others                            108                     36                             3.1 (1.6 to 5.9)        112                           32    1.5 (0.8 to 2.8)
  Preoperative use of oestrogen\*                                                                                                                      
   No                               1059                    149                            Reference               992                           216   Reference
   Yes                              781                     162                            1.2 (0.9 to 1.6)        709                           234   1.2 (0.9 to 1.5)
  Comorbidity (CCI)                                                                                                                                    
   0                                1328                    184                            Reference               1241                          271   Reference
   1--2                             425                     95                             1.5 (1.1 to 2.0)        384                           136   1.4 (1.1 to 1.8)
   3+                               87                      32                             3.1 (1.6 to 5.9)        76                            43    1.5 (1.0 to 2.4)
  Educational level†                                                                                                                                   
   Basic                            775                     142                            Reference               702                           215   Reference
   Secondary                        665                     105                            1.1 (0.8 to 1.5)        623                           147   1.0 (0.7 to 1.1)
   Higher                           362                     62                             1.3 (0.9 to 2.0)        342                           82    0.9 (0.6 to 1.3)
  Annual income                                                                                                                                        
   Low                              434                     103                            Reference               404                           133   Reference
   Middle                           930                     147                            0.9 (0.6 to 1.2)        847                           230   1.0 (0.8 to 1.3)
   High                             476                     61                             0.9 (0.6 to 1.4)        450                           87    0.9 (0.6 to 1.3)
  Year of surgery                                                                                                                                      
   1996--2006                       363                     96                             1.4 (0.9 to 2.2)        352                           107   0.9 (0.7 to 1.1)
   2007--2008                       692                     99                             Reference               628                           163   reference
   2009--2010                       785                     116                            1.0 (0.8 to 1.4)        721                           180   1.0 (0.8 to 1.4)

Results from multivariate logistic regression models on (1) short-term (0--60 days after surgery) and (2) long-term (61--356 days after surgery).

\*Women with at least one redeemed prescription of oestrogen within 365 days preceding the date of surgery.

†Unknown highest attained educational level: 40 women.

CCI, Charlson comorbidity index; Post op, postoperative; rpMUS, retropubic mid-urethral sling; toMUS, trans-obturator mid-urethral sling.

Stratified analyses according to the use of oestrogens before surgery showed that among users of oestrogen, the adjusted OR for short-term and long-term use of antibiotics for UTI after surgery increased to 3.3 (95% CI 2.3 to 4.8) and 5.2 (95% CI 3.7 to 7.3), respectively, [table 3](#BMJOPEN2013004051TB3){ref-type="table"}.

###### 

Stratified analyses according to use of oestrogen before surgery for UI to examine the association between preoperative use of antibiotics for urinary tract infection and postoperative use

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Preoperative oestrogen n   Preoperative antibiotics n   Crude OR (95% CI)\   Adjusted OR\* (95% CI)\   Crude OR (95% CI)\   Adjusted OR\* (95% CI)\   
                                                          Short-term           Short-term                Long-term            Long-term                 
  -------------------------- ---------------------------- -------------------- ------------------------- -------------------- ------------------------- ------------------
  Yes 943                    Yes\                         285\                 3.5 (2.5 to 5.0)          3.3 (2.3 to 4.8)     5.2 (3.8 to 7.2)          5.2 (3.7 to 7.3)
                             No                           658                                                                                           

  No 1208                    Yes\                         211\                 2.0 (1.3 to 2.9)          2.0 (1.3 to 3.0)     3.8 (2.7 to 5.2)          3.7 (2.6 to 5.3)
                             No                           997                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted for age, procedure type, comorbidity, educational level, annual income and calendar year of surgery.

Discussion {#s4}
==========

Among 2151 women undergoing surgery for UI, nearly one-fourth had redeemed at least one prescription of antibiotics for UTI preoperatively, and among preoperative users nearly half of the women also redeemed prescriptions of antibiotics for UTI within 61--365 days after surgery. Among preoperative users of antibiotics we found a 2--3-fold increased risk of short-term use of antibiotics for UTI after surgery, and a 4--5-fold increased risk of being long-term user. In women not using antibiotics for UTI before surgery only a minor proportion initiated use of antibiotics after surgery.

To ensure that our results were not influenced by effect modification of oestrogen use we stratified our analyses for preoperative use of oestrogen. In both strata we found an increased risk of postoperative antibiotic use for the exposed women. The risk estimates for short-term and long-term use were, however, higher among women using oestrogen preoperatively compared with women without prior oestrogen use.

The proportion of women with concomitant surgery for pelvic organ prolapse in our cohort of women with UI surgery was low, and this was as expected given the current practice in Scandinavia with a conservative approach of addressing the predominant problem of either pelvic organ prolapse or UI in sequential surgery.[@R33] Thus, our results were not influenced by a mixed cohort with both UI surgery and pelvic organ prolapse surgery.

Our study has several strengths: (1) it is population-based in the sense that this study covers all the relevant surgeries in a well-defined geographic area in Denmark, (2) the source of procedure codes in the NPR has high coverage and validity---the NPR records 99.4% of all discharges from hospitals in Denmark, and the procedures in the NRP have been validated showing a high quality of the data with positive predictive values of 94--100%,[@R34] (3) the access to high-quality data on prescriptions from the OPED that are representative for the Danish population,[@R24] (4) information on several confounders such as comorbidity and socioeconomic status, (5) complete information on the follow-up period for all included women, (6) outcome data on postoperative antibiotic prescriptions are recorded independently of prior antibiotic use, thus preventing differential misclassification of the outcome, (7) the antibiotics included in this study are UTI specific and are drugs of choice in Denmark for treating UTI and finally (8) the surgical procedures included have no other indications than UI, which strongly limits the number of alternative interpretations of our findings. Furthermore, the exclusion of antibiotics with other indications than UTI may even have led to an underestimation of the risk of UTI.

There are possible limitations to our study. We have no information on perioperative use of antibiotic, antibiotic given while the patient was still hospitalised, or results of urine culture. A redeemed prescription of antibiotics for UTI does not necessarily equal a UTI, and urine culture is not always performed prior to a prescription. Thus, empiric therapy is possible. To prevent UTI and other postoperative infections a perioperative single-dose of intravenous antibiotic is often used in Denmark.[@R37] However, perioperative antibiotic use is unlikely to be much different between exposed and unexposed cohorts and will thus not bias our relative risk estimates. In the short-term perspective after surgery we had no knowledge of postoperative catheter usage which is a limitation, especially since postoperative UTI is associated with catheter usage in the postoperative period,[@R38] [@R39] but again we have no reasons to believe that use of catheters differed among exposed and unexposed cohorts. We were not able to control for all potential confounders such as body mass index, parity, intraoperative bladder perforation or precise menopausal status, but the importance of these factors for the association examined in this study is not clear. We had no data on patient symptomatology, that is, whether stress UI, urgency UI, mixed UI or overactive bladder syndrome were predominant, or on urodynamic study, and it could have been interesting to further examine the users of UTI antibiotics (both before and after surgery) according to the type of UI symptomatology.

It is surprising that among women using antibiotics for UTIs before UI surgery, half of them have a continuing tendency to use these antibiotics after surgery. This is not explained by recurrent UI surgery in the study period of 1 year after surgery as only approximately 5% of women experienced a new surgery in our population. Possible explanations for the continuing tendency to UTI could be a genetic predisposition for UTI, an anatomic predisposition for UTI, or an increased awareness of UTI for both the women and their doctor.

On the basis of the flow chart in our study, we observed a tendency to continuing UTI among women with preoperative antibiotic use in short-term and long-term, postoperatively. To our knowledge, this is the largest, and only population-based, study examining the use of antibiotics for UTI in relation to surgery for UI and addressing the risk of short-term and long-term postoperative use of antibiotics for UTI among women with preoperative UTI. In addition, our study provides knowledge about which other factors than preoperative antibiotic were important for postoperative antibiotic use for UTI. We found that for short-term use procedure type (rpMUS, others), and high comorbidity were risk factors and for long-term use high comorbidity was a risk factor. Our study also showed that educational level and personal income did not seem to influence the risk of postoperative antibiotic use.

In Denmark, dipstick urine test is a part of the preoperative examination, and surgeons might feel encouraged to treat the women with antibiotics prior to surgery based on dipstick urine test without symptoms or urine culture in an attempt to try to minimise the risk of postoperative UTI.

According to the Danish Programme for the surveillance of antimicrobial consumption and resistance in bacteria from animals, food and humans, the resistance, especially in bacteria other than *Escherichia coli*, has increased during the last years. *E coli* is the most frequent cause of UTIs both in community-acquired and hospital-acquired UTIs.

Our study calls for further studies within this area---studies examining UTI before and after surgery according to different types of UI (stress UI, urgency UI, mixed UI), UTI in relation to surgery in especially postmenopausal women, issues regarding recurrent UTI and UI surgery, and if prophylactic antibiotic use (perioperative intravenous/prolonged oral antibiotics) could reduce the risk of postoperative UTI after UI surgery in a short-term and long-term perspective. Furthermore, it would be interesting to assess the use of similar antibiotics in the background population of women to examine whether there is an increased antibiotic burden associated with surgery for UI.

In conclusion, we found that one in four women undergoing surgery for UI was treated for UTI before surgery, and half of these women continued the tendency of UTI after surgery. In women not using antibiotics for UTI before surgery only a minor proportion initiated use of antibiotics for UTI after surgery. The strongest risk factor of postoperative use of antibiotics for UTI was the use of these antibiotics before surgery.
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